Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. - Wikidata - awgldk - TriplyDB

Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.

Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.

http://www.wikidata.org/entity/Q37240662

about

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins BRCA1 and Oxidative Stress "Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy.Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers.Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.Patient-derived heavy chain antibody targets cell surface HSP90 on breast tumors.Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.Systematic Identification and Assessment of Therapeutic Targets for Breast Cancer Based on Genome-Wide RNA Interference Transcriptomes mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin.RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance.Triapine potentiates platinum-based combination therapy by disruption of homologous recombination repair.Reverse the Resistance to PARP Inhibitors.Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.Refining the role of BRCA1 in combating oxidative stress.Advances in the approach to novel drug clinical development for breast cancer.Systems analysis of dynamic transcription factor activity identifies targets for treatment in Olaparib resistant cancer cells.Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches.ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells.Prediction of therapy response in ovarian cancer: Where are we now?Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.VCP inhibitors induce endoplasmic reticulum stress, cause cell cycle arrest, trigger caspase-mediated cell death and synergistically kill ovarian cancer cells in combination with Salubrinal.Identification of evolutionarily conserved DNA damage response genes that alter sensitivity to cisplatin.ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.RNA-sequencing dissects the transcriptome of polyploid cancer cells that are resistant to combined treatments of cisplatin with paclitaxel and docetaxel.Interactions Between Ataxia Telangiectasia Mutated Kinase Inhibition, Poly(ADP-ribose) Polymerase-1 Inhibition and BRCA1 Status in Breast Cancer Cells.CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair.The development of PARP as a successful target for cancer therapy.Break Breast Cancer Addiction by CRISPR/Cas9 Genome Editing.Acquired resistance of phosphatase and tensin homolog-deficient cells to poly(ADP-ribose) polymerase inhibitor and Ara-C mediated by 53BP1 loss and SAMHD1 overexpression.Estrogen receptor-α promoter methylation is a biomarker for outcome prediction of cisplatin resistance in triple-negative breast cancer.DNA-Targeted Precision Medicine; Have we Been Caught Sleeping?PARP inhibitors: Clinical utility and possibilities of overcoming resistance.ATM loss leads to synthetic lethality in BRCA1 BRCT mutant mice associated with exacerbated defects in homology-directed repair.Posttranscriptional Regulation of PARG mRNA by HuR Facilitates DNA Repair and Resistance to PARP Inhibitors.Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation.PARP inhibitors: the journey from research hypothesis to clinical approval.

P2860

Q26783551-AE72BA0A-30E9-448F-8286-4A772917E0CD Q28085364-9F2D3D86-D721-443B-9722-20FB83DA7A3F Q28388921-5957BC42-01CA-4397-ABD7-1ED3120BE440 Q33618910-01D621E3-1F6F-4BF3-AE56-EA1EE8A98BEC Q33698648-553C1042-BF70-4294-A4D2-CCCF0E6E0209 Q33917649-93C112F1-C341-472A-97C7-9A7D1028B691 Q34520145-8427E1AD-6189-40A2-AEA4-E1A40AB0D6D2 Q35763206-BA823EAB-3161-4C07-ACAC-C1713B747DD4 Q35895214-2F54513B-42BC-4A72-B732-60EC3E95BD9E Q36293047-B9A78336-B23B-486D-B263-6BF9DEFF351A Q36874139-ACEF3E1A-1B45-4525-BB1B-CB1A7AF64072 Q36921422-5A49086F-BA97-4638-85B1-4D08723856F5 Q37137877-977EB0FB-89A1-4DB0-9FEC-2B56D9C1E92B Q37174956-3B6770D8-3C4F-4C88-993F-625525697B2F Q37675896-F28E5085-8164-4DC6-BD54-A49D2D485F38 Q37684589-9594A8AC-F2F7-4BDA-988A-D9C1BC9FC197 Q37689775-E5CA2851-3B8A-4761-B5E5-5B349AC8DC88 Q38206546-39252AED-BDB2-4439-A7DC-0338BEACE4CE Q38711389-219EA597-1DB8-4FA1-96BE-29D0E5DEA54B Q38735426-130EE387-FE9B-4477-8561-D66A8DEAB7D3 Q38758230-777C574B-ACCB-4D5E-B9D5-19C99735991C Q39263260-BD85FC17-ED27-4F28-A877-22DF2934E998 Q41276800-82472BA9-D535-46E5-8AEF-A246A30DD088 Q41895056-2D9B74C3-635A-44F6-B5E9-654D3C86FA4F Q42292342-FC8DC30D-65E6-4D27-A1A5-584AA061037B Q42315217-EC7838BB-470E-4AE2-A6D0-D1FB041DD799 Q42777412-2A9AB6C5-C3D9-4FD6-BA02-3157CC58BEA6 Q42953216-D7820AD1-4F81-44D8-AAC6-C3C14CBE6039 Q43898530-177ED3FB-C155-4DD9-BE92-667E90B567CF Q46345647-9EE61822-EB7A-4AAB-958A-8DD84A22B5B4 Q47278103-FCC60E3B-12C0-4D39-9DF0-2890B937FF87 Q47561562-232D0816-36B3-4F27-B560-75D23D29ABAE Q48352256-39782827-4FB2-4155-AC46-002B91418659 Q49875019-F49E30F1-37B6-4B70-BA54-B81C1CE9DADA Q50006534-B143E637-16AE-43F4-ACDC-B3E52FFABB0C Q50076626-BFE592F5-3035-464B-986C-F909996DF69D Q50329367-72FDE32A-4E56-4731-9406-3B4F0EBCA9D7 Q50902460-DE6D44FA-79C8-430E-8F22-A445558097B1 Q52660676-5E746AE3-EB87-4C81-955F-587233852C0F Q53682668-F38600E1-A807-41D8-A550-D838506C5C52

P2860

Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.

http://www.wikidata.org/entity/Q37240662

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.

@en

Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.

@nl

type

label

Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.

@en

Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.

@nl

prefLabel

Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.

@en

Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.

@nl

P1433

Q37240662-9B69E85D-9EDB-471F-B2C7-7D84E18AD8A7

P1476

Q37240662-8E0E5243-BF99-4B12-A4D8-7D54943004BB

P2093

Q37240662-06F961C6-3CCE-4C08-9662-5409CF591A56

Q37240662-0CE4DF3A-A6C8-4919-9F5B-7B158511B1C4

Q37240662-16EDFFE1-FDD5-477C-ADC8-600E2799AAC1

Q37240662-1934DEE2-90C1-47A0-80A9-C4BC7CD7ECD6

Q37240662-23A2CA5D-853F-4E55-B0F3-C5A6B5D99349

Q37240662-3C4DFC2B-92B8-4696-A4C3-3923B36E3211

Q37240662-4D9C60EB-2217-4B70-A463-325BF41CD6FD

Q37240662-538883A0-C202-4EFF-AFA1-F50C9F0785B5

Q37240662-69BA26EC-D412-4EB2-B065-BF81884ECC9C

Q37240662-6AD4232F-22BC-4379-ACA6-FD9946EDDAA2

P2860

Q37240662-0314C3DA-C3EA-425C-A6C3-023D2449F4DE

Q37240662-15D296DE-F593-4D28-9AA3-237559CF2A68

Q37240662-1E06619B-8466-45B3-82CA-8AC61E4E797A

Q37240662-232C1B39-9522-4A07-8AC1-BB630F586ECF

Q37240662-282493BE-32A3-404E-8FF3-AD8CCC60B8C7

Q37240662-32A54F7D-5DD5-416D-AFF5-0A1518ADB267

Q37240662-35494D6D-57AF-4481-B510-C861AD59AC2C

Q37240662-36C3ABBC-9F92-4330-BE25-573E50C7450C

Q37240662-3AB7B25C-56B1-4701-B821-8E1756D11053

Q37240662-53C0C306-310A-410A-BEFA-69BEF0D7046F

P304

Q37240662-47DF9D29-5F0B-490D-AAF9-64FDD00D532E

P31

Q37240662-B68D4B26-8DC1-4442-B8BA-725A1B7880AB

P356

Q37240662-76C9648C-3D68-4100-A3B3-D0C46E87D160

P407

Q37240662-5675B069-1B2C-4B67-B552-1D746483685C

P433

Q37240662-B5AE1886-5367-460D-B5AD-47F818F652A4

P478

Q37240662-00C3809F-226C-4CB0-807F-0129AAE14AA6

P50

Q37240662-033F12D6-F837-4B33-A81A-8CB346146ED1

Q37240662-7C5EFA96-08A3-4F52-AF13-BD4C6052CCF9

P577

Q37240662-D31AC390-4B6C-4964-A470-C5011E8A4DEF

P5875

Q37240662-5A398BA1-D0D2-4382-B2CE-0B86F8489AE2

P698

Q37240662-A9AF287D-CE84-46A1-9F2C-B3F5AB0F1A42

P932

Q37240662-11531849-CA31-424A-A7B1-3ACBE61FFB04

P356

PNAS.1305170110

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.

@en

P2093

Alan D D'Andrea

http://www.w3.org/2001/XMLSchema#string

Alexander Miron

http://www.w3.org/2001/XMLSchema#string

Andrea J Bernhardy

http://www.w3.org/2001/XMLSchema#string

Anneka Wickramanayake

http://www.w3.org/2001/XMLSchema#string

Dipanjan Chowdhury

http://www.w3.org/2001/XMLSchema#string

Elizabeth M Swisher

http://www.w3.org/2001/XMLSchema#string

Geoffrey I Shapiro

http://www.w3.org/2001/XMLSchema#string

Joyce F Liu

http://www.w3.org/2001/XMLSchema#string

Lisa A Moreau

http://www.w3.org/2001/XMLSchema#string

Maria I Harrell

http://www.w3.org/2001/XMLSchema#string

P2860

PALB2 is an integral component of the BRCA complex required for homologous recombination repair

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers

Mutational processes molding the genomes of 21 breast cancers

Human CtIP promotes DNA end resection

Structural consequences of a cancer-causing BRCA1-BRCT missense mutation

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Association of BRCA1 with Rad51 in mitotic and meiotic cells

53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks

HSP90 and the chaperoning of cancer

P304

17041-17046

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1305170110

http://www.w3.org/2001/XMLSchema#string

P407

P433

42

http://www.w3.org/2001/XMLSchema#string

P478

110

http://www.w3.org/2001/XMLSchema#string

P50

Marzia Capelletti

Kristopher A Sarosiek

P577

2013-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257301948

http://www.w3.org/2001/XMLSchema#string

P698

24085845

http://www.w3.org/2001/XMLSchema#string

P932

3801063

http://www.w3.org/2001/XMLSchema#string